14 completed, 4 terminated, 3 active not recruiting, 3 withdrawn. 11 Phase 2, 5 Phase 3, 2 Not applicable, 2 Phase 1, 1 Early Phase 1.
Follow Carcinoid Syndrome: new trials by email Literature Review of Carcinoid Syndrome trials Research Report on Carcinoid Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CardioNETPOL National Registry of Carcinoid Heart Disease Observational Registry of Carcinoid Heart Disease - Carcinoid Heart Disease, Neuroendocrine Tumors | Not yet recruiting | National Institute of Cardiology, Warsaw, Poland | 120 | 2026-06-01 | 2026-03-04 | |
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Paltusotine, Placebo - Carcinoid Syndrome, Carcinoid | Phase 3 | Active not recruiting | Crinetics Pharmaceuticals Inc. | 141 | 2025-11-19 | 2026-10-15 |
| Fibrosis in Chronic and Delayed Myocardial Infarction 68Ga-FAPI and 18F-AlF-FAPI PET-MR - Aortic Stenosis, Chemotherapy Induced Systolic Dysfunction | Completed | University of Edinburgh | 50 | 2022-11-10 | 2026-08-12 | |
| Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome Randomized: 40 mg Paltusotine, Randomized: 80 mg Paltusotine - Carcinoid Syndrome, Carcinoid | Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 36 | 2022-04-22 | 2026-03-19 |
| Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease Transcatheter Tricuspid Valved Stent Graft - Tricuspid Regurgitation, Tricuspid Valve Disease | Not applicable | Active not recruiting | Queen Mary University of London | 15 | 2022-04-06 | 2026-05-08 |
| Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl Telotristat ethyl, Peptide Receptor Radionuclide Therapy, Placebo - Neuroendocrine Tumors, Carcinoid Syndrome | Phase 2 | Withdrawn | Chandrikha Chandrasekhara | 2021-03-03 | 2023-02-10 | |
| Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome Retifanlimab, Telotristat Ethyl - Advanced Neuroendocrine Neoplasm, Carcinoid Syndrome | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2021-03-01 | 2021-09-29 | |
| Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy Lutathera - Carcinoid Heart Disease, Carcinoid Syndrome | Phase 2 | Unknown | King's College Hospital NHS Trust | 20 | 2020-10-01 | 2020-08-04 |
| Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency Enterade®, Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0) - Neuroendocrine Tumor, Carcinoid Syndrome | Not applicable | Terminated | Vanderbilt-Ingram Cancer Center | 11 | 2019-11-04 | 2021-05-21 |
| Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs Amino Acid Based Medical Food/Drink - Neuroendocrine Tumors, Carcinoid Tumor of GI System | Phase 2 | Completed | Lowell Anthony, MD | 10 | 2018-12-06 | 2022-11-03 |
| AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm Carbon C 11 Alpha-methyltryptophan, Laboratory Biomarker Analysis, Positron Emission Tomography - Carcinoid Syndrome, Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 4 | 2018-06-20 | 2025-04-10 |
| Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO Xermelo - Carcinoid Syndrome | Completed | TerSera Therapeutics LLC | 223 | 2017-06-22 | 2024-07-24 | |
| Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation Sandostatin - Neuroendocrine Tumors, Carcinoid Syndrome | Phase 4 | Terminated | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 10 | 2016-02-02 | 2019-10-25 |
| An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors Dual-Energy Computed Tomography - Carcinoid Syndrome, Carcinoid Tumor | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 71 | 2015-09-23 | 2026-08-11 |
| Telotristat Etiprate for Carcinoid Syndrome Therapy Telotristat etiprate, Placebo - Carcinoid Syndrome | Phase 3 | Completed | Lexicon Pharmaceuticals | 76 | 2014-03-11 | 2018-02-26 |
| Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms Telotristat etiprate - Carcinoid Syndrome | Phase 3 | Completed | Lexicon Pharmaceuticals | 124 | 2014-01-14 | 2019-09-17 |
| An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males 500 mg [14C]-LX1606 - Carcinoid Syndrome | Phase 1 | Completed | Lexicon Pharmaceuticals | 8 | 2013-08-01 | 2013-10-23 |
| Study of Panitumumab in the Treatment of Carcinoid Syndrome Panitumumab - Carcinoid Syndrome | Phase 2 | Withdrawn | Boston Medical Center | 2013-07-01 | 2013-07-26 | |
| TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) Telotristat etiprate, Placebo-matching telotristat etiprate - Carcinoid Syndrome | Phase 3 | Completed | Lexicon Pharmaceuticals | 135 | 2013-01-08 | 2018-02-27 |
| Effects of Serotonin Excess on Bone in Carcinoid Syndrome Carcinoid Syndrome | Completed | Sheffield Teaching Hospitals NHS Foundation Trust | 52 | 2011-01-01 | 2012-06-15 |
Showing 20 of 26. Sign in to see all of them.
Serotonin Syndrome (26) · Neuroendocrine Tumors (10) · Carcinoid Tumor (7) · Carcinoid Heart Disease (3) · Diarrhea (3) · Carcinoid Tumors, Intestinal (2) · Aortic Valve Stenosis (1) · Flushing (1) · Heart Failure (1) · Heart Valve Diseases (1) · Tricuspid Valve Insufficiency (1)
Chemically-Induced Disorders (26) · Drug-Related Side Effects and Adverse Reactions (26) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Neoplasms, Germ Cell and Embryonal (14) · Neoplasms, Nerve Tissue (14) · Neuroectodermal Tumors (14) · Adenocarcinoma (8) · Carcinoma (8) · Neoplasms, Glandular and Epithelial (8) · Cardiovascular Diseases (4) · Heart Diseases (4) · Neuroendocrine Tumors (4) · Malignant Carcinoid Syndrome (3) · Pathological Conditions, Signs and Symptoms (3)
telotristat (6) · telotristat ethyl (4) · Octreotide (2) · Magnetic Resonance Spectroscopy (1) · Panitumumab (1) · Random Allocation (1) · TBR-760 (1) · alpha-methyltryptophan (1) · lanreotide (1) · lutetium Lu 177 dotatate (1)
Lexicon Pharmaceuticals (6) · Ipsen (3) · Crinetics Pharmaceuticals Inc. (2) · M.D. Anderson Cancer Center (2) · Barbara Ann Karmanos Cancer Institute (1) · Boston Medical Center (1) · Chandrikha Chandrasekhara (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · King's College Hospital NHS Trust (1) · Lowell Anthony, MD (1) · National Institute of Cardiology, Warsaw, Poland (1) · Queen Mary University of London (1) · Sheffield Teaching Hospitals NHS Foundation Trust (1) · TerSera Therapeutics LLC (1)
United States (15) · United Kingdom (11) · France (6) · Germany (6) · Poland (6) · Spain (6) · Belgium (5) · Israel (5) · Italy (5) · Canada (4) · Netherlands (4) · Sweden (4) · Australia (3) · Brazil (3) · Czechia (3)
Pablo Lapuerta, MD (4) · Ajaykumar Morani (1) · Al B Benson, MD (1) · Andreas Baumbach (1) · Anthony Shields (1) · Chandrikha Chandrasekharan, MD (1) · Daniel M Halperin, MD (1) · Doug Fleming, MD (1) · Ivan Borbath, Prof (1) · Janine North, BS (1) · Jennifer S Walsh, PhD (1) · Kevan Hartshorn, MD (1) · Lowell Anthony (1)
PMID 32146619, PMID 34598813, PMID 25012985, PMID 25636046, PMID 26917486, PMID 27041406, PMID 27214300, PMID 29330194, PMID 29724499, PMID 30477789, PMID 31655936, PMID 31754316, PMID 32157590, PMID 33940581, PMID 36262750
2009 (2), P30CA022453 (1)